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Cytochrome P-450 was purified to apparent homogeneity from the brain microsomes of phenobarbital-treated rats. The
specific content of the purified P-450 was 12.7 nmol/mg of protein. NADPH-cytochrome P-450 reductase (reductase) was
also purified to apparent homogeneity from brain microsomes. The specific content was 34.7,mol of cytochrome c
reduced/min per mg of protein. The reduced carbon monoxide spectrum of purified P-450 exhibited a peak at 450 nm.
Both the P-450 and the reductase moved as single bands on SDS/PAGE. The molecular masses of the purified P-450 and
the reductase were determined to be 53.3 and 72.0 kDa respectively. The purified brain P-450 cross-reacted with
antibodies to rat liver P-4501IB1/11B2 when examined by Western immunoblotting, but no immunological similarity was
observed with rat liver P-450IA1/A2 or P-45011E1. Purified rat brain reductase cross-reacted with antibodies to rat liver
reductase. Further, immunoblot experiments with untreated rat and human brain microsomes using antisera to the
purified rat brain P-450 and reductase indicated that these forms of P-450 and NADPH-cytochrome P-450 reductase exist
constitutively in rat and human brain. Purified rat brain P-450 was reconstituted with purified NADPH-cytochrome
P-450 reductase, deoxycholate and dilauroyl glyceryl 3-phosphocholine. NADPH-dependent N-demethylation of
aminopyrine and morphine was observed in the reconstituted system. The catalytic-centre activities were 80.25 and
38.2 nmol of formaldehyde formed/min per nmol of P-450 respectively. The reconstituted system had a comparatively
lower catalytic-centre activity for 7-ethoxycoumarin O-de-ethylase (10.5 nmol of product formed/min per nmol of P-450).
INTRODUCTION
Cytochromes P-450, a family of haem-containing enzymes,
exist in multiple forms and are involved in both detoxification
and bioactivation of xenobiotics [1]. The liver is the major organ
involved in P-450-mediated xenobiotic metabolism, and multiple
forms of hepatic P-450 have been purified from experimental
animals and humans [2,3]. Cytochrome P-450 has also been
purified from extrahepatic organs, e.g. kidney [4], lung [5,6] and
ventral prostate [7]. The brain is the target for a number of toxic
compounds and psychoactive drugs [8], and a role for en-
vironmental toxins in the aetiopathogenesis of certain neuro-
degenerative disorders has been suggested [9]. Studies on brain
cytochrome P-450 and NADPH-cytochrome P-450 reductase
have revealed that these proteins could have diverse functions in
the brain. Thus evidence has been presented indicating that the
DM,/o-l binding site could be a member of the cytochrome P-
450 family [10], and that NADPH-cytochrome P-450 reductase
shares partial sequence similarity with NADPH diapharose [11]
and nitric oxide synthase [12]. In light of the above, further
elucidation of the components of the P-450 system in the brain
is of interest. The purification and characterization of various
forms of P-450 and NADPH-cytochrome P-450 reductase from
the brain may help identify the diverse roles of these proteins in
this organ.
Previous studies from our laboratory have demonstrated the
presence of substantial amounts of P-450 in mouse brain [13], rat
brain [14] and human autopsy brain [15]. The co-localization of
P-450 and reductase in the neuronal soma has also been
demonstrated [16]. The cytochrome P-450 content in the rat
brain is typically one-tenth of the hepatic levels, and it exists in
multiple forms which are selectively induced by phenobarbital
and 3-methylcholanthrene [14]. Pretreatment with phenobarbital
induces the cerebral P-450 (1880% induction) and reductase
(270% induction) activities, and this is accompanied by selective
induction of the mono-oxygenase (namely, aminopyrene N-
demethylase and morphine N-demethylase) activities known to
be mediated by P-4501IB1/IIB2 [14]. Chronic administration of
phenytoin is also known to induce the cytochrome P-450 level
in mouse brain [17]. We report here the isolation and
characterization ofcytochrome P-450 and NADPH-cytochrome
P-450 reductase from the brain microsomes of rats treated with
phenobarbital, the reconstitution of mono-oxygenase activity
using these purified components and immunological evidence for
the constitutive presence of this P-450 system in both rat and
human brain.
MATERIALS AND METHODS
Materials
Dithiothreitol, phenylmethanesulphonyl fluoride, Tris, sodium
cholate, DEAE-Sephacel, Sepharose 4B, Lubrol PX, Triton N-
101, 2',5'-ADP-agarose, dilauroyl glyceryl-3-phosphocholine,
sodium deoxycholate, aminopyrine and 7-ethoxycoumarin were
purchased from Sigma Chemical Co. All other chemicals were
purchased locally and were of analytical grade.
Treatment of animals
One hundred male adult Wistar rats (each weighing 200-220 g)
were given phenobarbital (0.025 %, w/v) in their drinking water
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for 70 days. Thereafter, the animals were administered pheno-
barbital daily (80 mg/kg body weight, intraperitoneally) for 10
days. The animals were killed 24 h after the last dose.
Preparation of microsomes
Microsomes from brains of phenobarbital-treated rats were
prepared as described elsewhere [18]. The microsomes were
resuspended in 0.1 M-potassium phosphate buffer (pH 7.25) con-
taining 30 % (v/v) glycerol, 1 mM-EDTA, 1 mM-dithiothreitol,
22 /LM butylated hydroxytoluene and 0.1 mM-phenylmethane-
sulphonyl fluoride (buffer A). The buffer had been previously
bubbled through with nitrogen gas. The microsomes were divided
into portions and stored in liquid nitrogen. Microsomes also
were prepared from 10 untreated male rat brains as described
above.
Cortical microsomes were prepared from human autopsy
brain. The deceased, aged 35 years, was a victim of traffic
accident with no known neurological disorders. The patient did
not receive any anticonvulsant medication prior to death. The
interval between death and autopsy was 3 h.
Cytochrome P-450 was estimated from the reduced carbon
monoxide spectrum [19]; NADPH-cytochrome c reductase ac-
tivity was measured as described [20] during the various stages of
purification. Protein was estimated by a dye-binding method [21]
and the results were compared with those obtained using the
method of Lowry et al. [22].
Purification of P450 and NADPH-P450 reductase from brains
of phenobarbital-treated rats
All procedures were carried out at 4 °C and all buffers used for
purification were bubbled with nitrogen gas prior to use.
Microsomes were diluted to final concentration of 2 mg/ml in
buffer A. To this was added 20% (w/v) sodium cholate dropwise
for 15 min to a final concentration of 0.6% (w/v) with gentle
stirring. After stirring for an additional 90 min at 4 °C, the
solution was centrifuged at 100000 g for 1 h and the supernatant
was collected.
The supernatant (200 mg of microsomal protein) was loaded
on to a column (2.5 cm x 35 cm) packed with octylamino
Sepharose 4B, which had been previously equilibrated with
1 litre of 0.1 M-potassium phosphate buffer (pH 7.25) containing
1 mM-EDTA, 1 mM-dithiothreitol, 20% (v/v) glycerol and 0.7%
(w/v) sodium cholate. The flow rate was adjusted to 0.5 ml/min.
The column was washed with the above buffer (500 ml) con-
taining 0.46% (w/v) sodium cholate. The flow rate was 1 ml/min.
Cytochrome P-450 was eluted as a sharp peak with 0.1 M-
potasium phosphate buffer (pH 7.25) containing 1 mM-EDTA,
1 mM-dithiothreitol, 20% (v/v) glycerol, 0.3 % (w/v) sodium
cholate and 0.08% (v/v) Triton N-101. The absorbance of the
eluate was monitored at 417 nm.
After the elution of the P-450, the reductase was eluted from
the octylamino Sepharose 4B column with 0.1 M-potassium
phosphate buffer (pH 7.4) containing 20% (v/v) glycerol, 1 mM-
EDTA, 1 mM-dithiothreitol and 0.37% (w/v) sodium deoxy-
cholate. NADPH-cytochrome c reductase activity was monitored
in the eluted fractions.
The cytochrome P-450-containing fractions from the
octylamino Sepharose 4B column were pooled and concentrated
to half the original volume using an Amicon PM-30 membrane,
and dialysed overnight against 10 vol. of a solution containing
20% (v/v) glycerol, 0.1 mM-dithiothreitol and 0.1 mM-EDTA.
The cytochrome P-450-containing fractions were dialysed further
against 0 mM-potassium phosphate buffer (pH 7.7) containing
0.1 mM-EDTA, 0.1 mM-dithiothreitol, 20 %/_ (v/v) glycerol, 0.2%
(w/v) sodium cholate and 0.1 % (v/v) Lubrol PX.
Following dialysis, the non-diffusible material was applied to
a DEAE-Sephacel column (2.5 cm x 30 cm) which had been
previously equilibrated with 1 litre of 10 mM-potassium
phosphate buffer (pH 7.7) containing 0.1 mM-EDTA, 0.1 mm-
dithiothreitol, 20% (v/v) glycerol, 0.2% (w/v) sodium cholate
and 0.1% (v/v) Lubrol PX, at a flow rate of 1 ml/min. The
major amount of P-450 was eluted with the above buffer. Two
small peaks with very low P-450 concentrations were eluted with
the above buffer containing NaCl (200 and 300 mm respectively).
The major fraction that was eluted with the equilibration buffer
was passed through a column (1.5 cm x 25 cm) packed with
XAD-2 beads, at a flow rate of 0.25 ml/min. The eluant was
concentrated using an Amicon PM-30 membrane and dialysed
overnight against 20 vol. of 10 mM-Tris/acetate buffer (pH 7.4)
containing 0.1 mM-EDTA, 0.1 mM-dithiothreitol and 20% (v/v)
glycerol. The non-diffusible material containing P-450 was
divided into portions and stored at 70 °C until further analysis.
The NADPH-cytochrome P-450 reductase-containing
fractions which eluted from the octylamino Sepharose-4B column
were pooled and loaded directly (at a flow rate of 0.25 ml/min)
on to a small column of 2',5'-ADP-agarose, which was
equilibrated with 0.25 M-potassium phosphate buffer (pH 7.25)
containing 0.1 mM-EDTA, 0.1 mM-dithiothreitol, 20% (v/v)
glycerol, 2 uM-FMN and 0.1 % (v/v) Lubrol PX. The column
was washed with 30 mM-potassium phosphate buffer (pH 7.7)
containing 0.1 mM-EDTA, 0.1 mM-dithiothreitol, 20% (v/v)
glycerol, 2 1tM-FMN and 0.1 % (w/v) sodium deoxycholate. The
NADPH-cytochrome c reductase activity was eluted as a sharp
peak with the above buffer containing 2'-AMP (5 mM). The
fractions were pooled, concentrated and dialysed against 5 vol.
of 10 mM-Tris/acetate buffer (pH 7.4) containing 0.1 mM-EDTA,
0.1 mM-dithiothreitol and 20% (v/v) glycerol. The non-diffusible
material containing the reductase was divided into portions and
stored at -70 'C.
Immunochemical studies
Antisera to purified rat brain P-450 and reductase were raised
in male New Zealand White rabbits [4]. Antisera to purified rat
liver P-4501IB1/IIB2, P-450A1A/IA2 and reductase were raised
in rabbits and characterized as described elsewhere [13,14,16].
Antiserum to rat liver P-45011E1 was a gift from Dr. B. J. Song,
NIAAA, Rockville, MD, U.S.A., and this antiserum was
characterized as described [23].
The purified brain proteins (P-450 and reductase) were
subjected to SDS/PAGE using 10% acrylamide (see Fig. la) or
a gradient of 3-10% acrylamide (see Fig. Ib). The gels were
stained with Coomassie Blue [24]. The molecular masses of
purified brain P-450 and reductase were determined using
standard molecular mass markers. The purified proteins and
microsomes from untreated and phenobarbital-rat liver and
brain and human autopsy brain were also subjected to SDS/
PAGE and then transferred on to nitrocellulose membranes for
examination by immunoblot [25]. After the incubation with
antisera, the blots were immunostained as described [13].
Reconstitution of purified P450 and reductase
The catalytic activity of purified rat brain P-450 in a
reconstituted system containing purified rat brain reductase and
dilauroyl glyceryl-3-phosphocholine was investigated as de-
scribed [5] with certain modifications as detailed below. The
system was reconstituted in 50 mM-Tris buffer (pH 7.4), con-
taining 20 mM-MgCl2, 40,uM-dilauroyl glyceryl-3-phospho-
choline, 0.18 1sM-sodium deoxycholate, purified rat brain re-
ductase (3.5,tg), 1 mm substrate and purified rat brain P-450
(30-60 pmol). The reaction was initiated by addition ofNADPH
to a final concentration of 1 mm. The total volume was I ml. The
formaldehyde formed during the N-demethylation of amino-
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Table 1. Specific content of rat brain P450 at various stages of purification
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Total protein Specific activity Total activity Overall Purification
Fraction (mg) (nmol of P-450/mg) (nmol of P-450) yield (%) (fold)
Microsomes 400 0.22 88.8 100 -
Solubilized microsomes 200 0.38 75.4 85 1.6
Elution from octylamino Sepharose 4B 33.8 1.7 56.0 63 7.5
Elution from DEAE-Sephacel 0.7 12.7 9.4 10.6 57.4
(10 mM-potassium phosphate)
Table 2. Specific activity of rat brain NADPH-P450 reductase at various stages of purification
Reductase activity is expressed as nmol ofcytochrome c reduced/min per mg of protein. Reductase activity was determined in the presence of 0.6 %
(w/v) sodium cholate and 2 sM-FMN. In the absence of sodium cholate and FMN, the reductase activity in microsomes was 55.2 nmol of
cytochrome c reduced/min per mg of protein.
Total protein Specific activity Total activity Overall Purification
Fraction (mg) (nmol/min per mg) (nmol/min) yield (%) (fold)
Microsomes 400 162 68800 100 -
Solubilized microsomes 200 247 49400 76 1.5
Elution from octylamino Sepharose 4B 20 2160 43100 67 13.0
Elution from 2'5'-ADP-agarose 0.97 34700 33700 52 214
pyrine or morphine was determined using NASH reagent [26].
The assay of 7-ethoxycoumarin O-de-ethylase activity in the
reconstituted system was carried out as described [27].
RESULTS
Purification ofP-450 from brain microsomes of phenobarbital-
treated rats was carried out using a combination of octylamino
Sepharose 4B and DEAE-Sephacel chromatography as described
earlier [5]. The summary of the purification of P-450 is given in
Table 1. A total of 85% of the brain microsomal P-450 was
recovered on solubilization of microsomes with sodium cholate.
The chromatography of solubilized microsomes on octylamino
Sepharose 4B resulted in an increase in the specific content of P-
450 by 44 %. The recovery from this step was 74 %. The eluant
from the octylamino Sepharose 4B column was dialysed and
(a) 1 2 (b) 1 2
Fig. 1. SDS/PAGE of purified brain P450 (a) and NADPH-P-450
reductase (b)
(a) Lane 1, purified brain P-450 (5,g). Lane 2, standard molecular
mass markers (top to bottom): BSA (66 kDa), egg albumin (45 kDa),
glyceraldehyde-3-phosphate dehydrogenase (36 kDa), carbonic
anhydrase (29 kDa), trypsinogen (24 kDa), trypsin inhibitor
(20 kDa) and lactalbumin (14.2 kDa). (b) Lane 1, purified reductase
(5,g). Lane 2, standard molecular mass markers (top to bottom):
myosin (200 kDa), fl-galactosidase (116 kDa), phosphorylase b
(97 kDa), BSA (66 kDa), egg albumin (45 kDa), carbonic anhydrase
(29 kDa).
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applied to a DEAE-Sephacel column, and was eluted in low-
ionic-strength buffer (10 mM-potassium phosphate buffer). How-
ever, a small quantity of P-450 was eluted as two small peaks
with 200 and 300 mM-NaCl. The specific content of P-450 in
these fractions eluting in 10 mM-phosphate buffer was high
(12.74 nmol of P-450/mg of protein). The overall recovery of
P-450 was 10.6 %.
The results of reductase purification from phenobarbital-
treated rat brain are shown in Table 2. Rat brain reductase was
separated from P-450 on an octylamino Sepharose 4B column
and eluted with buffer containing sodium deoxycholate; the
recovery was 87 % of the enzyme activity present in solubilized
microsomes. Affinity chromatography on 2',5'-ADP-agarose
resulted in the separation of purified brain reductase. The enzyme
was purified 214-fold and the specific activity was 34.7,tmol of
cytochrome c reduced/min per mg of protein.
SDS/PAGE of the purified P-450 and reductase is shown in
Figs. l(a) and l(b). The proteins appear as single bands on the
gel. The molecular mass of brain P-450 was determined to be
53.3 kDa and that of the reductase was determined to be
72.0 kDa.
The reduced carbon monoxide spectrum of purified P-450
exhibited a single peak at 450 nm (Fig. 2). The absence of any
peak at 420 nm indicated that purified P-450 was devoid of the
denatured form of P-450, namely cytochrome P-420.
The purified P-450 efficiently catalysed the N-demethylation of
aminopyrine in a reconstituted system containing reductase,
deoxycholate-and dilauroyl glyceryl-3-phosphocholine (Table 3).
The catalytic-centre activity for aminopyrine N-demethylation
was 80.3 nmol of formaldehyde formed/min per nmol of P-450.
The presence of reductase was essential for P-450 catalytic
activity. The absence of deoxycholate or dilauroyl glyceryl-3-
phosphocholine caused a substantial decrease in the turnover
number (Table 3).
The capability of the reconstituted P-450 system to metabolize
various other substrates was also examined (Table 4). Among the
substrates tested, the highest catalytic-centre activity was
observed for aminopyrine, followed by morphine. The de-
ethylation of 7-ethoxycoumarin was catalysed to a lesser extent.
Antisera raised against purified rat brain P-450 identified a
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Fig. 2. Reduced carbon monoxide spectrum of purified rat brain P450
The concentration ofprotein was 15 ,ug/ml. The broken line indicates
the baseline.
Fig. 3. Immunoblots of purified brain P450 and untreated rat and human
brain microsomes following immunostaining with antisera to purified
rat brain P450 (lanes 1, 2 and 3), and immunoblot of purified brain
P450 following immunostaining with antisera to various forms of
rat liver P450 (lanes 4, 5 and 6)
Amounts loaded: purified rat brain P-450; 2 /4g (lane 1), untreated
rat brain microsomes, 30 ,ug (lane 2); human brain cortical
microsomes, 40 ,ug (lane 3). Immunoblotting of purified brain P-450
(2 ,ug/lane) is shown following immunostaining with antisera to rat
liver P450IIBI/IIB2 (lane 4), rat liver P-450IA1/IA2 (lane 5) and
rat liver P-450IIE1 (lane 6).
1 2 3 4
Table 3. Aminopyrine N-demethylase activity in a reconstituted system
containing purified brain P-450 and NADPH-P450 reductase
Reconstitution was carried out in 50 nM-Tris buffer (pH 7.4) con-
taining MgCl2 (20 mM), sodium deoxycholate (0.18 /sM), purified rat
brain reductase (3.5 /zg), dilauroyl glyceryl-3-phosphocholine
(40 /tM), purified rat brain P-450 (30 or 60 pmol), aminopyrine
(I mM) and NADPH (1 mM) in a total volume of 1 ml. The
formaldehyde formed was measured as described in the Materials
and methods section. The assays were performed in duplicate. ND
indicates that activity was not detectable.
Turnover number
(nmol of formaldehyde
formed/min per nmol
System of P-450)
Complete system 80.3
No deoxycholate 32.5
No dilauroyl glyceryl-3-phosphocholine 24.0
No reductase ND
No P-450 ND
No aminopyrine ND
Table 4. Activity of purified phenobarbital-treated rat brain microsomal
P450 towards various substrates in a reconstituted system
Assays were carried out as described in the Materials and methods
section and were performed in duplicate.
Substrates (1 mM) Activity
Aminopyrine
Morphine
7-Ethoxycoumarin
80.3*
38.2*
10.5t
* nmol of formaldehyde formed/min per nmol of P-450.
t nmol of 7-hydroxycoumarin formed/min per nmol of P-450.
single protein band in untreated rat brain microsomes and
human brain microsomes, when examined by Western immuno-
-bIotting (Fig. 3). These bands co-migrated with purified rat brain
P-450.
A typical Western immunoblot of purified rat brain P-450
incubated with antisera to rat liver P-450IA1/IA2, P-4501B1B/
Fig. 4. Immunoblots of brain microsomes from control (lanes 1 and 3) and
phenobarbital-treated rats (lanes 2 and 4) following immunostaining
with antiserum to purified rat brain P450
The amount of brain microsomal protein contents in lanes 1 and 2
was 50 ,tg, and that in lanes 3 and 4 was 75 ,ug.
12 3 4
Fig. 5. Immunoblots of purified brain NADPH-P450 reductase and
untreated rat and human brain microsomes, following staining with
antiserum to purified rat brain reductase
Lane 1, purified rat brain reductase (1 ug/lane); lane 2, untreated rat
brain microsomes (30 ,ug/lane); lane 3, human brain cortical
microsomes (40,sg/lane); lane 4, immunoblot of purified brain
reductase (2,ug/lane) immunostained with antiserum to rat liver
reductase.
IIB2 or P-45011E1 exhibited cross-reactivity only with antisera to
rat liver P-450IIB1/IIB2 (Fig. 3).
Immunoblot experiments with control and phenobarbital-
treated rat brain microsomes using antisera to purified rat brain
P-450 reVealed the presence of a single band in each case.
However, the band was substantially more intense in the lane
containing phenobarbital-treated rat brain microsomes com-
pared with control rat brain microsomes (Fig. 4).
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Antisera raised against purified rat brain NADPH-P-450
reductase identified a single protein band in untreated rat brain
microsomes and human brain microsomes when examined by
Western immunoblotting (Fig. 5). These bands co-migrated with
purified rat brain reductase. A typical immunoblot of purified rat
brain reductase incubated with antiserum to rat liver reductase is
shown in Fig. 5. The immunoblot revealed a single protein band,
indicating cross-reactivity between purified rat brain reductase
and antiserum to rat liver reductase.
DISCUSSION
Evidence for the presence of P-450 in rat brain microsomes
was first presented more than a decade ago [28,29], but to date
the P-450 from brain microsomes has not been purified to
homogeneity. Partial purification of rat brain microsomal P-450
had been reported previously [30]; the specific content of the
partially purified brain P-450 was 0.18 nmol of P-450/mg of
protein, which was about one-hundreth the specific content of
purified hepatic P-450. The partial purification of brain P-450
using whole brain homogenate had also been reported by Warner
et al. [31]; the specific content of P-450 was 1-3 nmol of P-
450/mg of protein. Since the mitochondrial P-450 content in
brain was reported to be relatively high [32], the specific content
of the partially purified P-450 from whole brain homogenate
conceivably-could-have included contributions from both micro-
somal and mitochondrial P-450s. The purification of the brain
microsomal P-450 offered us a particular challenge, since this
organ contains very low amounts of P-450. Further, brain
microsomal P-450 had been reported to be very unstable during
the purification process [30]. Similarly, the purification of P-450
from other extrahepatic organs had been reported to be especially
difficult due to the relatively low amounts of P-450 present. For
example, the specific content of the purified P-450 from rat
ventral prostate was reported to be 8-10 nmol of P-450/mg of
protein [7] and the specific content of P-450 purified from rat
kidney was reported to be 10-12.6 nmol of P-450/mg of protein
[4].
Isolation of brain microsomes in the presence of glycerol and
dithiothreitol [8] helps preserve the integrity of P-450, and higher
levels of P-450 (0.08 nmol/mg of protein) were detectable in
untreated rat brain compared with earlier reports (0.03 nmol/mg
of protein). Following prolonged treatment with phenobarbital
the P-450 levels in brain are induced, resulting in a higher P-450
content (0.22 nmol/mg of protein; 250% induction). Therefore
phenobarbital-induced rat brain microsomes were used for
purification of this form of P-450 from rat brain.
In the present study the purified brain P-450 had a specific
content of 12.74 nmol of P-450/mg of protein. The P-450 from
phenobarbital-treated rat brain was eluted with low-ionic-
strength buffer (10 mm potassium phosphate) from a DEAE-
Sephacel column. Similar behaviour has been reported for rabbit
lung P-450 [5] and the P-450 from Drosophila melanogaster [33].
SDS/PAGE of purified rat brain P-450 revealed the apparently
homogeneous nature of the preparation (Fig. la). The absorption
maximum of the reduced carbon monoxide spectrum of purified
brain P-450 was indeed observed at 450 nm.
The NADPH-P-450 reductase was purified to apparent hom-
ogeneity from the phenobarbital-treated rat brain microsomes.
SDS/PAGE analysis of the purified rat brain reductase revealed
that the final preparation was apparently homogeneous (Fig. I b).
NADPH-cytochrome c reductase activity detectable in micro-
somes increased significantly in the presence of sodium cholate
and FMN. The specific activity of the purified brain reductase
was lower than that of a similar preparation from rat liver (40
compared with 70 ,tmol of cytochrome c reduced/mg of protein
[34]).
In the reconstituted system, the purified rat brain P-450
exhibited a high catalytic-centre activity for the metabolism of
aminopyrine (80.3 nmol of product formed/min per nmol of P-
450). The purified P-450 from phenobarbital-treated rat liver was
also reported to have a high catalytic-centre activity for the
metabolism of aminopyrine (85 nmol of product formed/min per
nmol of P-450) and a low catalytic-centre activity for the
metabolism of 7-ethoxycoumarin (9 nmol of product formed/
min per nmol of P-450) [2]. We observed similar results with
the reconstituted system from brain; the catalytic-centre activity
for 7-ethoxycoumarin O-de-ethylase was low (10.5 nmol of
product formed/min per nmol of P-450) (Table 4).
The purified rat brain P-450 exhibited immunological cross-
reactivity with antiserum to rat liver P-4501IB1/lIB2, but no
cross-reactivity was observed with antisera to P-450A1A/IA2,
and P-45011E1. The purified rat brain reductase also exhibited
cross-reactivity with antiserum to rat liver reductase, indicating
immunological similarity between purified brain reductase and
rat liver reductase.
In summary, a cytochrome P-450 and an NADPH-cytochrome
P-450 reductase have been purified successfully from brains of
phenobarbital-treated rats and reconstituted mono-oxygenase
activities have been demonstrated. Immunoblot experiments
with untreated rat and human brain microsomes, using antisera
to the purified rat brain P-450 and reductase, indicated that this
form of P-450 and reductase exist constitutively in rat and
human brains. The characterization of the phenobarbital-
inducible form of P-450 in brain is of particular interest in view
of the extensive use of phenobarbital as an anticonvulsant agent.
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